4.1 Therapeutic indications
The treatment of tumour-induced hypercalcaemia
The prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, hypercalcaemia and bone pain) in patients with breast cancer with bone metastases, or multiple myeloma with bone lesions, in addition to specific treatment of the tumour
Paget's disease of bone
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.
Medthority will not be held liable for explicit or implicit errors, or missing data.
Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).